참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 1-Methylpiperazine | HCID 53167 | — |
| 반응물 | N-(5-Bromopyrazin-2-YL)acetamide | HCID 58574049 | — |
| 시약 | Potassium tert-butoxide | HCID 23665647 | — |
| 촉매 | Tris(1,1-dimethylethyl)phosphine | HCID 83681 | — |
| 촉매 | Bis(dibenzylideneacetone)palladium | HCID 9811564 | — |
| 용매 | Dimethylformamide | HCID 6228 | — |
| 생성물 | N-[5-(4-methylpiperazin-1-yl)pyrazin-2-yl]acetamide | HCID 59983941 | 79.51% |
반응 단계
1-methylpiperazine (2.318 g, 23.14 mmol), N-(5-bromopyrazin-2-yl)acetamide (1 g, 4.63 mmol), tri-tert-butylphosphine (1.873 g, 9.26 mmol), tris(dibenzylideneacetone)dipalladium (0.085 g, 0.09 mmol) and potassium 2-methylpropan-2-olate (1.039 g, 9.26 mmol) were suspended in DMF (9.26 ml) and sealed into a microwave tube. The reaction was heated to 120 °C for 40 minutes in the microwave reactor and cooled to RT. The mixture was diluted with methanol and acidified with HCl, then the solution was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NH3/MeOH and pure fractions were evaporated to dryness to afford N-(5-(4-methylpiperazin-1-yl)pyrazin-2-yl)acetamide (0.866 g, 80 %) as a dark oil. Used without further purification.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-96727602adb24b28af9c737e24f7315c |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|